Gilead Sciences on Monday agreed to purchase Kite Pharma for $11.9 million, reports Reuters. Here are four things to know about the deal. 1. Gilead will pay $180 per share for Kite Pharma in an ...

Kite Pharma, a Gilead Company (NASDAQ:GILD), and Daiichi Sankyo Co., Ltd. (OTCPK:DSNKY) jointly announced the revision of their 2017 partnership pact, which gave Daiichi Sankyo exclusive rights to ...

Gilead’s Kite Pharma has tied down a licensing deal for Refuge Biotechnologies’ gene expression platform in hopes of developing new blood cancer treatments and plans to take flight with a new ...

Gilead’s oncology arm Kite Pharma announced an expansion of its deal with Arcellx that will give Kite access to ACLX-001, a BCMA-targeted CAR-T cell therapy for multiple myeloma. Under the deal ...

Kite Pharma's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead Sciences company is touting its position as the only cell therapy player able to make ...

– Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion Activities in Japan After the Marketing Authorization Transfer – SANTA MONICA, Calif. & TOKYO--(BUSINESS ...

Gilead Sciences' Kite Pharma cell therapy unit is undergoing a business review that will result in layoffs to about 7% of the organization’s workforce. In a letter sent to staff this week that was ...

Santa Monica-based Kite Pharma announced March 5 that the Food and Drug Administration has granted accelerated approval for the company’s principal drug, Yescarta, for the treatment of adult patients ...

Biotech giant Gilead Sciences Inc. and its Kite Pharma Inc. subsidiary in Santa Monica are buying Cell Design Labs Inc. for up to $567 million as the battle to develop cancer-targeting cell therapies ...

SANTA MONICA, Calif., Feb. 3, 2015 /PRNewswire/ -- Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) ...

Shareholders can measure the ROI of Gilead Sciences' Kite Pharma acquisition not in years, but in days. For much of 2016 and 2017, all the news for Gilead seemed to be negative. Sales for the ...

– Daiichi Sankyo to Transfer Yescarta Marketing Authorization in Japan to Gilead Sciences K.K. – – Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion ...